SCHEMBL2563716

SCHEMBL2563716

CCCCCCCC[C@@H](CCCCCCC(=O)O)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.53
FFAR1 O14842 3/20 0.53
GPR84 Q9NQS5 7/20 0.50
PPARG P37231 7/20 0.50
PPARD Q03181 7/20 0.50
PPARA Q07869 7/20 0.50
HDAC11 Q96DB2 5/20 0.50
TSHR P16473 4/20 0.50
PTPN1 P18031 3/20 0.50
ALDH1A1 P00352 3/20 0.50
TLR2 O60603 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
FABP4 P15090 2/20 0.50
KMT2A Q03164 2/20 0.50
ALOX15 P16050 2/20 0.50
HSD17B10 Q99714 2/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
SLC22A8 Q8TCC7 1/20 0.50
MEN1 O00255 1/20 0.50
ESR1 P03372 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18540778 1.00 FFAR4 (0.53) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL2563715 1.00 FFAR4 (0.53) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL9461433 1.00 FFAR4 (0.53) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL28725173 0.94 FFAR4 (0.45) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL517865 0.94 FFAR4 (0.42) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL24305225 0.87 FFAR4 (0.43) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL9268517 0.87 GPR84 (0.47) FFAR4FFAR1GPR84TSHRKMT2A
SCHEMBL19439385 0.87 GPR84 (0.47) FFAR4FFAR1GPR84TSHRKMT2A
SCHEMBL9268527 0.87 GPR84 (0.47) FFAR4FFAR1GPR84TSHRKMT2A
SCHEMBL5696052 0.87 GPR84 (0.47) FFAR4FFAR1GPR84TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021086610-A1 COMPOSITIONS AND METHODS OF USE VERA BIOTECHNOLOGY, INC. (US) 2021-05-06 WO disclosed
US-20200046786-A1 COMPOSITIONS AND METHODS OF USE Shah, Kirit (US) 2020-02-13 US disclosed
US-10478464-B2 Compositions and methods of use Shah, Kirit (US) 2019-11-19 US disclosed
EP-2381950-B1 hydroxyhexadecanoic acid for the treatment of cancer VANAS ONCOLOGY (US) 2013-11-13 EP disclosed
EP-2381950-A2 COMPOSITIONS AND METHODS OF USE Vanas Oncology (US) 2011-11-02 EP disclosed
US-20100209543-A1 COMPOSITIONS AND METHODS OF USE VANAS ONCOLOGY (US) 2010-08-19 US disclosed
US-20100209543-A1 COMPOSITIONS AND METHODS OF USE VANAS ONCOLOGY (US) 2010-08-19 US disclosed
WO-2010083311-A2 COMPOSITIONS AND METHODS OF USE VANAS ONCOLOGY (US) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100209543-A1 COMPOSITIONS AND METHODS OF USE MKI67, VHL, CCNC FFAR4 4783/4885FFAR1 4689/4885GPR84 4272/4885
US-20200046786-A1 COMPOSITIONS AND METHODS OF USE MKI67, VHL, CCNC FFAR4 4783/4885FFAR1 4689/4885GPR84 4272/4885
US-10478464-B2 Compositions and methods of use MKI67, VHL, CCNC FFAR4 4783/4885FFAR1 4689/4885GPR84 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.